All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
Collection of tumor and blood samples from subjects enrolled in the main study (LEE011A2404) will undergo proteomic and ctDNA analysis respectively to better understand mechanisms of response and resistance to ribociclib in combination with letrozole therapy.
HR+ HER2 Breast Cancer
Dec 28, 2018
Dec 30, 2020
(Child, Adult, Older Adult)
600 mg ribociclib oral once daily
letrozole 2.5 mg oral once daily
must have been eligible and participated in the main LEE011A2404 study
must provide consent to collect samples
if consent not given to collect samples
Patients without either archival tumor tissue block or slides accessible